Caplin Point Laboratories Ltd (BOM:524742)

Q1 2026 Caplin Point Laboratories Ltd Earnings Call Transcript

Aug 7, 2025 / 10:30 AM GMT

Release Date Price: ₹2057.45 (+6.71%)

Transcript

Key Points

Positve

Caplin Point Laboratories Ltd (BOM:524742) reported an overall revenue growth of 11.1%, with significant contributions from both ROW and US markets.
The company has successfully expanded its presence in Latin America, with plans to enter larger geographies such as Chile, Colombia, and Mexico.
Caplin Point Laboratories Ltd (BOM:524742) has a strong cash position, with liquid assets amounting to 2,207 crore, enabling future investments without borrowing.
The company's US business has reached profitability within the first couple of quarters of launch, with 21 products already launched and 15 more planned.
Caplin Point Laboratories Ltd (BOM:524742) is focusing on asset-light models and value-added products, including biosimilars and peptides, to enhance profitability.

Negative

The company faces geopolitical risks, particularly in the US market, where potential tariffs on pharmaceuticals could impact growth.
Caplin Point Laboratories Ltd (BOM:524742) has delayed the timeline for its OSD facility from Q4 2026 to Q3 2027, indicating potential project management challenges.
The company has experienced some management turnover, with recent resignations and new appointments in senior positions.
There is uncertainty regarding the market size and growth potential for the company's GLP-1 products in Latin America.
Caplin Point Laboratories Ltd (BOM:524742) acknowledges that its oncology segment may take time to contribute significantly to the bottom line, given the competitive and regulated nature of the market.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CAPL.NS - Caplin Point Laboratories Ltd
Q1 2026 Caplin Point Laboratories Ltd Earnings Call
Aug 07, 2025 / 10:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to the Kaplan Point Laboratories Limited Q1S5 26 earnings conference call hosted by Dollar Capital Market Private Limited. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing, then 0 on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Zagula Mali from Dollar Capital Private Limited.

Thank you and over to you, sir.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.